Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Corporate Update (December 2021)
26 slides from Chimeric Therapeutics's corporate update, Dec 1, 2021
Slide 1: Transformative Portfolio Expansion: The CORE-NK Platform
THE ASX LEADER IN CELL THERAPY TRANSFORMATIVE PORTFOLIO EXPANSION THE CORE-NK PLATFORM A CLINCALLY VALIDATED, OFF THE SHELF NATURAL KILLER CELL PLATFORM
Slide 2: Transformative Portfolio Expansion
CORE-NK Platform A platform Triples Extends technology Chimeric’s Chimeric’s clinical that can be pipeline development leveraged to adding 5 new program with 5 Transformative develop multiple new therapies cell therapy assets new clinical trials by 2023 Portfolio Expansion Broadens Chimeric’s Abilit
Slide 3: The Most Robust and Advanced Portfolio and Pipeline in Australia
THE MOST ROBUST AND ADVANCED PORTFOLIO AND PIPELINE IN AUSTRALIA 7 Unique Assets 8 Clinical Trials by 2023 10+ Disease Areas
Slide 4: Chimeric Pipeline Development Strategy
CHIMERIC PIPELINE DEVELOPMENT STRATEGY • 2 novel individualized (autologous) CAR T cell therapies • Exploration of opportunities with alternative cell types and cell sources Novel Designs T Cells Individualized NK Cells (autologous) CLTX CLTX CDH17 Phase 1 CAR T CAR T CAR T ongoing in Phase 1cancer
Slide 5: Why Natural Killer (NK) Cells?
WHY NATURAL KILLER (NK) CELLS? Natural killer cells are superior immune cells Natural killer cells are part of our immune system and have a natural ability to identify and kill tumour cells. (they’re named for this “natural” killing ability) Natural killer cells are also able to produce cytokines th
Slide 6: Why Off the Shelf?
WHY OFF THE SHELF? Off the shelf therapies offer benefits and convenience to individualized therapies Healthier Scalable Rapidly Ability to starting manufacturing available, reach more material with reduced costs off the shelf patients 6
Slide 7: Early Stage, Off the Shelf, NK Cell Platforms are Driving Significant Value
Early Stage, Off the Shelf, NK Cell Platforms are Driving Significant Value Ph. 1 non-engineered NK cell platform Preclinical non-engineered Preclinical non-engineered Preclinical CAR NK products (2) NK cell platform NK cell platform January 2021 June 2021 June 2021 Collaboration Collaboration Colla
Slide 8: CORE-NK Platform
Chimeric Therapeutics Off the Shelf, Natural Killer Cell Platform CORE-NK Platform Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform 8
Slide 9: Investment Highlights
INVESTMENT HIGHLIGHTS CORE-NK PLATFORM Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform § An off the shelf, natural killer cell platform technology that will be leveraged to develop multiple new therapies § Clinical validation of the platform with a complete Phase
Slide 10: The CORE-NK Platform
THE CORE-NK PLATFORM A Novel Strategy to Enhance NK Cells Natural Abilities Dr David Wald is a clinician-scientist at Case Western Reserve University in Cleveland, Ohio. With an interest in cancer drug development Dr Wald has focused his research on using natural killer cells to eliminate colorectal
Slide 11: CORE-NK Platform Cells
CORE-NK Platform Cells Enhancing the Natural Cancer-Fighting Power of NK cells Natural Killer CORE-NK (NK) Cell Platform Cell Natural killer cells are found in our CORE-NK cells are made by bodies normally and are able to activating and expanding recognize and kill cancer cells- but natural killer c
Slide 12: Phase 1 Clinical Trial
CORE-NK PLATFORM PHASE 1 CLINICAL TRIAL PATIENT ELIGIBILITY PHASE 1 DOSE ESCALATION BLOOD CANCERS Acute Myeloid Leukemia Phase 1 Clinical Trial Plasma Cell Myeloma Dr David Wald, Case Comprehensive Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Cancer Center Chronic Myeloid Leukemia Chronic
Slide 13: CORE-NK Platform (CHM 0201) Phase 1 Clinical Trial Complete
CORE-NK PLATFORM (CHM 0201) PHASE 1 CLINICAL TRIAL COMPLETE PRIMARY COMPLETION 11 PATIENTS ENROLLED 9 PATIENTS DOSED JUNE 2021 SOLID TUMOURS COMPLETION OF ALL DATA CURRENTLY PENDING AND BLOOD CANCERS 3 DOSE LEVELS DATA ANTICIPATED 2022 13
Slide 14: CORE-NK Platform (CHM 0201): What Do We Do With It?
CORE-NK PLATFORM (CHM 0201) WHAT DO WE DO WITH IT? Next Generation CORE-NK Platform 1. Further enhance the CORE-NK platform with next generation technologies for development as a combination therapy CHM 0201 2. CAR-NK Products CORE-NK Fast-forward development of supercharged CAR NK products using ou
Slide 15: CORE-NK Platform (CHM 0201): What Do We Do With It?
CORE-NK PLATFORM (CHM 0201) WHAT DO WE DO WITH IT? 1. Next Generation CORE-NK Platform CHM 0201 2. CAR-NK Products CORE-NK Platform 3. Leverage the CORE-NK Platform 15
Slide 16: Next Generation CORE-NK Platform
1. NEXT GENERATION CORE-NK Platform Further enhancing the cancer-fighting power of the CORE-NK platform cells CHM 0301 CHM 0201 Next Generation Enhancements Next Gen CORE-NK CORE-NK Platform Platform 16
Slide 17: CHM 0301 Next Generation CORE-NK Platform
CHM 0301 NEXT GENERATION CORE-NK Platform Development in Blood Cancers as Combination Therapy Acute Myeloid B Cell Multiple Leukemia Malignancies Myeloma • Cancer of the bone marrow • Type of non-Hodgkin • Cancer of the plasma cells in and blood that generally lymphoma that originates in the bone ma
Slide 18: CAR-NK Products
2. CAR-NK PRODUCTS HOW DO YOU TURN A CORE-NK CELL INTO A CAR-NK? CORE-NK CAR-NK Platform Cell Cell CAR-NK The Chimeric products are Antigen made by Receptor then inserting Insertion of gets expressed Chimeric Chimeric on the cell Antigen Antigen surface Receptor Receptors supercharging (CARs) into t
Slide 19: Chimeric Supercharged CAR-NK Products
CHIMERIC SUPERCHARGED CAR-NK PRODUCTS LEVERAGING OUR CHIMERIC ANTIGEN RECEPTORS CLTX CHM 1301 CAR CLTX CAR-NK CDH17 CAR CHM 2301 CDH17 CAR-NK 19
Slide 20: Transformative Portfolio Development
TRANSFORMATIVE PORTFOLIO DEVELOPMENT A DIVERSIFIED PIPELINE WITH CUTTING EDGE INNOVATION Novel Design T Cells NK Cells Autologous Allogeneic (personal) (off-the-shelf) CHM 1101 CHM 0201 CHM 0301 CHM 1301 CHM 2301 CHM 3301 CHM 2101 (CORE-NK (Next Gen. (CLTX (CDH17 (Undisclosed (CLTX CAR T) (CDH17CAR
Slide 21: Leverage the CORE-NK Platform
3. LEVERAGE THE CORE-NK PLATFORM IDENTIFY COLLABORATION AND LICENSING OPPORTUNITIES Development of 4 CAR NK / CAR T $50M upfront +$50M equity investment + products $3B milestones + double digit royalties $30M upfront + Development of 3 CAR NK products $612/ per CAR NK; $1.8B potential Development of
Slide 22: CORE-NK Platform Development Plan
CORE-NK PLATFORM DEVELOPMENT PLAN 4 NEW CLINICAL TRIALS BY 2023 ü CORE-NK platform Phase 1 • Development of CLTX CAR-NK • Phase 1 clinical trial: Next clinical trial completed at and CDH17 CAR-NK products generation CORE-NK platform Case Western • Phase 1 CAR NK clinical trial • Initiate development
Slide 23: Establishing Value in the NK Development Field
ESTABLISHING VALUE IN THE NK DEVELOPMENT FIELD Planned Time to Phase 1 Clinical Trial Company Market Cap 2021 2022 2023 CHM 0201 (CORE- NK) CHM 0301 (Next Generation CORE-NK) $90M AUS CHM 1301 (CLTX CAR-NK) CHM 2301 (CDH17 CAR-NK) CHM 3301 (Undisclosed CAR-NK) CD19 $948M USD CD19+ CD79 CD133+ EGFR C
Slide 24: The Most Experienced Cell Therapy Team in Australia
THE MOST EXPERIENCED CELL THERAPY TEAM IN AUSTRALIA GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION Development of over 25 CELL THERAPIES including Jennifer Dr Eliot Dr Li Dr Syed 4/5 CHOW BOURK REN OF THE RIZVI Chief Operating VP, Business and VP, Technical FDA-APPROVED Chief Medical
Slide 25: Transforming Chimeric Therapeutics
The ASX Leader in Cell Therapy & an Emerging Global Cell Therapy Company Transforming Chimeric Therapeutics A clinically validated, off the shelf NK Cutting edge cell therapy portfolio platform technology that can be with 7 innovative assets using leveraged to develop multiple new alternative cell t
Slide 26: Contact Information
CONTACT INFORMATION Jennifer Chow Paul Hopper Chief Executive Officer Executive Chairman and Managing Director Cell: +61 406 671 515 Cell: +1 908-723-8387 paulhopper@lifescienceportfolio.com jchow@chimerictherapeutics.com
Chimeric Therapeutics — Corporate Update (December 2021) on 6ix